Galectin-3 in Heart Failure: An Update of the Last 3 Years

Carolin Gehlken, Navin Suthahar, Wouter C. Meijers, Rudolf A. de Boer*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

72 Citations (Scopus)
8 Downloads (Pure)

Abstract

Galectin-3 plays a role in tissue inflammation, repair, and fibrosis. This article specifically focuses on heart failure (HF), in which galectin-3 has been shown to be a useful biomarker in prognosis and risk stratification, especially in HF with preserved ejection fraction. Experimental research has shown that galectin-3 directly induces pathologic remodeling of the heart, and is therefore considered a culprit protein in the development of cardiac fibrosis in HF, with potentially relevant clinical implications. In summary, galectin-3 is a biomarker and biotarget in cardiac remodeling and fibrosis and future research will target galectin-3-centered diseases.

Original languageEnglish
Pages (from-to)75-92
Number of pages18
JournalHeart failure clinics
Volume14
Issue number1
DOIs
Publication statusPublished - Jan-2018

Keywords

  • Galectin-3
  • Heart failure
  • Fibrosis
  • Galectin-3 inhibitor
  • Biomarker
  • Prognosis
  • PRESERVED EJECTION FRACTION
  • MODIFIED CITRUS PECTIN
  • PROGNOSTIC VALUE
  • CARDIOVASCULAR-DISEASE
  • MYOCARDIAL FIBROSIS
  • RISK STRATIFICATION
  • GENERAL-POPULATION
  • PREDICTIVE-VALUE
  • PERFORMANCE-CHARACTERISTICS
  • SERIAL MEASUREMENTS

Cite this